Please login to the form below

Not currently logged in
Email:
Password:

Schering-Plough highlights product pipeline

Global healthcare company Schering-Plough presented its product portfolio to shareholders this week and highlighted several products that are close to market

Global healthcare company Schering-Plough presented its product portfolio to shareholders this week and highlighted several products that are close to market.

The company's chairman and CEO, Fred Hassan, explained how, with nine drugs currently in phase III trials and another three in pre-registration, he believes Schering-Plough currently has one of the best pipelines in the industry and he expects market exclusivity for most key prescription products to continue for several years to come.

Schering-Plough's current portfolio includes an antiplatelet agent Thrombin Receptor Antagonist (TRA), which is currently in phase III trials and has the potential to be a blockbuster.

Simponi, which is licensed to Schering-Plough by Centocor for use in various countries outside the US, is an anti-TNF agent for inflammatory and autoimmune disorders. It is currently under review in the EU for three indications and is in phase III trials in the US for one indication.

Hassan also pointed out that its hepatitis C drug, boceprevir, has proved effective without the side effects, (a rash) of rival medicines.

Dr Thomas P Koestler, executive vice president and president of Schering-Plough Research Institute, said: "Our R&D innovation is visible in our pipeline projects, six of which have been designated 'fast track' by the US Food and Drug Administration (FDA)." He added: "We are pleased that R&D now has the potential to add enormous value to the company's already well-protected marketed product portfolio."

Shareholders were also informed about a range of other medicines in development including two projects for Alzheimer's.

26th November 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics